Curis (CRIS) Net Income towards Common Stockholders (2010 - 2026)

Curis (CRIS) reported Net Income towards Common Stockholders of -$11.4 million for Q1 2026, down 7.78% on a YoY basis from -$12.4 million in Q1 2025, and down 159.11% quarter-over-quarter from $19.4 million in Q4 2025.

Curis (CRIS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Curis has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$11.4 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 7.78% year-over-year to -$11.4 million; the trailing twelve-month figure through Mar 2026 stood at -$8.4 million (up 80.04% YoY), and the FY2025 full-year result was -$7.6 million, up 82.53% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$11.4 million, down from $19.4 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $19.4 million in Q4 2025, with the low at -$16.1 million in Q1 2022.
  • Historically, Net Income towards Common Stockholders has averaged -$9.8 million across 5 years, with a median of -$11.6 million in 2023.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 62.27% — and 2025, when it surged 301.25%.
  • Curis' Net Income towards Common Stockholders stood at -$11.3 million in 2022, then declined by 3.38% to -$11.7 million in 2023, then grew by 17.88% to -$9.6 million in 2024, then surged by 301.25% to $19.4 million in 2025, then sank by 159.11% to -$11.4 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$11.4 million (Q1 2026), $19.4 million (Q4 2025), and -$7.7 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - -13.56 Mn
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 2.50 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -14.46 Mn
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -3.63 Mn
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.71 Bn 91.71 Bn - -56.48 Mn
10 Curis 8.27 Mn -6.73 Mn - -11.44 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -11.44 Mn
Dec 31, 2025 19.36 Mn
Sep 30, 2025 -7.73 Mn
Jun 30, 2025 -8.59 Mn
Mar 31, 2025 -10.62 Mn
Dec 31, 2024 -9.62 Mn
Sep 30, 2024 -10.09 Mn
Jun 30, 2024 -11.80 Mn
Mar 31, 2024 -11.88 Mn
Dec 31, 2023 -11.71 Mn
Sep 30, 2023 -12.18 Mn
Jun 30, 2023 -11.96 Mn
Mar 31, 2023 -11.56 Mn
Dec 31, 2022 -11.33 Mn
Sep 30, 2022 -13.29 Mn
Jun 30, 2022 -15.94 Mn
Mar 31, 2022 -16.11 Mn
Dec 31, 2021 -13.62 Mn
Sep 30, 2021 -11.05 Mn
Jun 30, 2021 -11.73 Mn